At this time, I would like to welcome everyone to the Dexcom Inc. fourth quarter 2024 earnings release conference call. All lines have been placed on mute to prevent any background noise. After the ...

Looking forward, DexCom's management has reiterated its fiscal year 2025 forecast, anticipating revenue growth of 14% with a ...

DexCom specializes in continuous glucose monitoring systems, primarily focusing on individuals managing diabetes. Its innovative CGM systems, like the G6 and the newer G7, offer real-time glucose ...

At this time, I would like to welcome everyone to the Dexcom Inc. fourth quarter 2024 ... Following our prepared remarks, we will open the call up for your questions. At that time, we ask analysts ...

Canaccord Genuity analyst William Plovanic maintains DexCom with a Buy and raises the price target from $99 to $103. Price Action: DXCM stock is up 6.22% at $89.32 at last check Friday.

This shift allows us to delve into its present market position and performance Current Position of DexCom With a trading volume of 4,506,895, the price of DXCM is up by 6.21%, reaching $89.31.

Continuous glucose monitors are small, wearable devices that track blood sugar levels in real-time. While the devices are commonly prescribed to diabetics to titrate medications (e.g. insulin) to ...

A screenshot from an urgent field safety notice of a diagram showing the Dexcom G6 receiver. Dexcom (Nasdaq:DXCM) recently issued an urgent field safety notice in Europe warning of a potential issue ...